Ainos Seeks FDA Nod For Mid-Stage Covid-19 Study
Ainos, Inc. (NASDAQ: AIMD) has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for conducting a Phase 2 trial of its drug candidate VELDONA, for treatment of mild symptoms related to COVID-19.